Summarize with:

When an investigator has a financial interest related to a human subjects study, the Institutional Review Board (IRB) needs to know about it before it approves the research. The conflict of interest (COI) office reviews the disclosure and decides whether a management plan is needed. The IRB then considers that information in its own review of risks to participants, including whether the consent form should mention the interest. The two determinations are separate. The information they depend on should not be. This post covers why the IRB needs COI information, where the handoff breaks and how to build a working COI and IRB workflow.

Key takeaways

  • The COI committee decides on conflicts and management plans. The IRB decides whether the research is approvable with those conflicts in view.
  • Most failures are timing failures: the IRB approves before the COI review is finished, or a mid-study change never reaches the IRB.
  • A disclosure question in the IRB submission, linked to the COI review, closes the most common gap.
  • Departmental COI review can catch conflicts early, but it needs clear routing so it does not become another delay.

Why Does the IRB Need Conflict of Interest Information?

Two sets of rules meet here. For research funded by the Public Health Service (PHS), institutions must collect investigators' significant financial interests, decide whether they amount to a financial conflict of interest, and manage any conflict they find, under 42 CFR 50 Subpart F. Many institutions apply the same process to all research, whatever the funding source.

The IRB has its own reason to care. Its job is to judge risks to participants and the adequacy of informed consent. A financial interest in the study's outcome can affect how participants are recruited, how data are interpreted and what participants should be told. Federal human subjects guidance encourages IRBs to consider investigator financial interests as part of that judgment.

There is also the IRB itself. Under 45 CFR 46.107(e), an IRB member with a conflicting interest may not take part in the initial or continuing review of that project, except to provide information the IRB requests. That is a separate question from investigator conflicts, but the same disclosure discipline supports both.

Where Does the COI and IRB Handoff Break Down?

The COI office and the IRB usually work well on their own. The gaps sit between them.

  • The IRB does not know a disclosure exists. The submission has no COI question, or the answer is not linked to the COI office's review, so the IRB approves without the information.
  • Timing does not line up. The IRB meets before the COI committee has reviewed the disclosure, and the study is approved with the conflict still unresolved.
  • The management plan never reaches the IRB. The COI committee requires disclosure in the consent form, but the IRB approved the consent form a week earlier.
  • Mid-study changes are missed. An investigator's financial interest changes after approval, and the IRB only learns at continuing review, or not at all.
  • Departmental review is informal. Department chairs are asked to review disclosures, but by email and without a deadline, so it becomes a hidden delay.

Each gap leaves the institution exposed. Participants may not be told what they should be told, and the institution may not be able to show that conflicts were considered before approval.

How Should COI Disclosures Flow Into IRB Review?

A reliable COI and IRB workflow has six steps: disclose, screen, review in the department where policy requires it, determine and manage, share with the IRB, and update over the life of the study.

  1. Ask at submission. Every IRB submission asks whether any investigator has a related financial interest. A yes links to the investigator's current disclosure.
  2. Screen the disclosure. COI staff review the disclosure against institutional policy and the PHS regulations where they apply.
  3. Route for departmental review where policy requires it. If your policy uses departmental COI submission or chair review, route it with a set response time and a clear escalation path.
  4. Determine and manage. The COI committee or designated official decides whether a conflict exists and approves any management plan, such as disclosure in the consent form or independent data monitoring.
  5. Share the outcome with the IRB. The determination and management plan are visible to the IRB before its review, and the IRB records how it considered them.
  6. Update through the life of the study. New or changed interests are disclosed promptly and routed to both the COI office and the IRB.

The rule that matters most is simple. The IRB should not grant final approval while a related COI review is open, unless institutional policy sets out an exception.

What to Track When Disclosures Change Mid-Study

COI disclosure tracking does not end at approval. For each active study with a related financial interest, track:

  • The current disclosure and the date it was last updated
  • The COI determination and the management plan, with its conditions
  • Whether consent documents reflect the management plan
  • Annual disclosure updates and new disclosures within the required time frame
  • Any required reporting to the funding agency for PHS-funded research
  • IRB acknowledgment of each change

Linking these items to the IRB protocol, rather than holding them only in the COI office, lets both offices see the same status when a study is audited.

What Should a System Support?

When you evaluate systems for this workflow, ask each vendor to walk through one disclosure from submission to IRB approval as a scripted scenario. Look for:

  • A COI question in the IRB submission that links to the investigator's current disclosure
  • Routing for departmental COI submission with response times and escalation
  • Management plans visible to IRB staff and reviewers
  • A clear signal to the IRB when a related COI review is still open
  • Alerts to both offices when a disclosure changes during the study

Where Key Solutions Fits

Key Solutions offers Conflict of Interest (eCOI) alongside the Human Subjects (IRB) module in eProtocol by Key Solutions, for institutions that want disclosures and IRB review handled in a coordinated way.

The system supports the process. Investigators remain responsible for accurate disclosure, the COI committee remains responsible for conflict determinations and management plans, and the IRB remains responsible for its approval decision.

15+ Years Focused on Life Sciences Research · ISO 27001:2022 Certified · Built for Complex Research Environments

If your COI and IRB offices are coordinating disclosures by email, Request a Demo. We start with a short conversation about how both offices work today, then show a walkthrough built around your environment.

Request a Demo

Frequently Asked Questions

The COI committee or a designated institutional official normally makes the conflict determination and approves the management plan. The IRB considers that plan in its review and can require additional protections for participants. Keeping the roles separate, with shared information, avoids both duplication and gaps.

Ask the disclosure question at IRB submission, not after review, so the COI office can start at the same time. Set response times for departmental and COI review. Most delays come from starting the COI review late rather than from the review itself.

The PHS regulations apply to PHS-funded research, but many institutions apply one COI policy to all research. That consistency is simpler for investigators and reduces the risk that a conflict in an industry-funded study is never considered.

Define in policy what counts as late and what happens next, such as a retrospective review and an IRB notification. Apply it consistently. For PHS-funded research, late disclosure can trigger specific review and reporting obligations, so involve the COI office immediately.

A financial conflict of interest management plan sets out the steps an institution takes to reduce or eliminate bias from an investigator's conflict. Common measures include disclosure to participants and the public, independent monitoring, changes to the investigator's role, or reducing the financial interest.

Departmental COI review is a step in which a department chair or designee reviews an investigator's disclosure before or alongside the central COI office. It brings local knowledge of the research and the investigator's role. It works best with set timelines and clear routing.

Summarize with:

When an investigator has a financial interest related to a human subjects study, the Institutional Review Board (IRB) needs to know about it before it approves the research. The conflict of interest (COI) office reviews the disclosure and decides whether a management plan is needed. The IRB then considers that information in its own review of risks to participants, including whether the consent form should mention the interest. The two determinations are separate. The information they depend on should not be. This post covers why the IRB needs COI information, where the handoff breaks and how to build a working COI and IRB workflow.

Key takeaways

  • The COI committee decides on conflicts and management plans. The IRB decides whether the research is approvable with those conflicts in view.
  • Most failures are timing failures: the IRB approves before the COI review is finished, or a mid-study change never reaches the IRB.
  • A disclosure question in the IRB submission, linked to the COI review, closes the most common gap.
  • Departmental COI review can catch conflicts early, but it needs clear routing so it does not become another delay.

Why Does the IRB Need Conflict of Interest Information?

Two sets of rules meet here. For research funded by the Public Health Service (PHS), institutions must collect investigators' significant financial interests, decide whether they amount to a financial conflict of interest, and manage any conflict they find, under 42 CFR 50 Subpart F. Many institutions apply the same process to all research, whatever the funding source.

The IRB has its own reason to care. Its job is to judge risks to participants and the adequacy of informed consent. A financial interest in the study's outcome can affect how participants are recruited, how data are interpreted and what participants should be told. Federal human subjects guidance encourages IRBs to consider investigator financial interests as part of that judgment.

There is also the IRB itself. Under 45 CFR 46.107(e), an IRB member with a conflicting interest may not take part in the initial or continuing review of that project, except to provide information the IRB requests. That is a separate question from investigator conflicts, but the same disclosure discipline supports both.

Where Does the COI and IRB Handoff Break Down?

The COI office and the IRB usually work well on their own. The gaps sit between them.

  • The IRB does not know a disclosure exists. The submission has no COI question, or the answer is not linked to the COI office's review, so the IRB approves without the information.
  • Timing does not line up. The IRB meets before the COI committee has reviewed the disclosure, and the study is approved with the conflict still unresolved.
  • The management plan never reaches the IRB. The COI committee requires disclosure in the consent form, but the IRB approved the consent form a week earlier.
  • Mid-study changes are missed. An investigator's financial interest changes after approval, and the IRB only learns at continuing review, or not at all.
  • Departmental review is informal. Department chairs are asked to review disclosures, but by email and without a deadline, so it becomes a hidden delay.

Each gap leaves the institution exposed. Participants may not be told what they should be told, and the institution may not be able to show that conflicts were considered before approval.

How Should COI Disclosures Flow Into IRB Review?

A reliable COI and IRB workflow has six steps: disclose, screen, review in the department where policy requires it, determine and manage, share with the IRB, and update over the life of the study.

  1. Ask at submission. Every IRB submission asks whether any investigator has a related financial interest. A yes links to the investigator's current disclosure.
  2. Screen the disclosure. COI staff review the disclosure against institutional policy and the PHS regulations where they apply.
  3. Route for departmental review where policy requires it. If your policy uses departmental COI submission or chair review, route it with a set response time and a clear escalation path.
  4. Determine and manage. The COI committee or designated official decides whether a conflict exists and approves any management plan, such as disclosure in the consent form or independent data monitoring.
  5. Share the outcome with the IRB. The determination and management plan are visible to the IRB before its review, and the IRB records how it considered them.
  6. Update through the life of the study. New or changed interests are disclosed promptly and routed to both the COI office and the IRB.

The rule that matters most is simple. The IRB should not grant final approval while a related COI review is open, unless institutional policy sets out an exception.

What to Track When Disclosures Change Mid-Study

COI disclosure tracking does not end at approval. For each active study with a related financial interest, track:

  • The current disclosure and the date it was last updated
  • The COI determination and the management plan, with its conditions
  • Whether consent documents reflect the management plan
  • Annual disclosure updates and new disclosures within the required time frame
  • Any required reporting to the funding agency for PHS-funded research
  • IRB acknowledgment of each change

Linking these items to the IRB protocol, rather than holding them only in the COI office, lets both offices see the same status when a study is audited.

What Should a System Support?

When you evaluate systems for this workflow, ask each vendor to walk through one disclosure from submission to IRB approval as a scripted scenario. Look for:

  • A COI question in the IRB submission that links to the investigator's current disclosure
  • Routing for departmental COI submission with response times and escalation
  • Management plans visible to IRB staff and reviewers
  • A clear signal to the IRB when a related COI review is still open
  • Alerts to both offices when a disclosure changes during the study

Where Key Solutions Fits

Key Solutions offers Conflict of Interest (eCOI) alongside the Human Subjects (IRB) module in eProtocol by Key Solutions, for institutions that want disclosures and IRB review handled in a coordinated way.

The system supports the process. Investigators remain responsible for accurate disclosure, the COI committee remains responsible for conflict determinations and management plans, and the IRB remains responsible for its approval decision.

15+ Years Focused on Life Sciences Research · ISO 27001:2022 Certified · Built for Complex Research Environments

If your COI and IRB offices are coordinating disclosures by email, Request a Demo. We start with a short conversation about how both offices work today, then show a walkthrough built around your environment.

Request a Demo

Frequently Asked Questions

The COI committee or a designated institutional official normally makes the conflict determination and approves the management plan. The IRB considers that plan in its review and can require additional protections for participants. Keeping the roles separate, with shared information, avoids both duplication and gaps.

Ask the disclosure question at IRB submission, not after review, so the COI office can start at the same time. Set response times for departmental and COI review. Most delays come from starting the COI review late rather than from the review itself.

The PHS regulations apply to PHS-funded research, but many institutions apply one COI policy to all research. That consistency is simpler for investigators and reduces the risk that a conflict in an industry-funded study is never considered.

Define in policy what counts as late and what happens next, such as a retrospective review and an IRB notification. Apply it consistently. For PHS-funded research, late disclosure can trigger specific review and reporting obligations, so involve the COI office immediately.

A financial conflict of interest management plan sets out the steps an institution takes to reduce or eliminate bias from an investigator's conflict. Common measures include disclosure to participants and the public, independent monitoring, changes to the investigator's role, or reducing the financial interest.

Departmental COI review is a step in which a department chair or designee reviews an investigator's disclosure before or alongside the central COI office. It brings local knowledge of the research and the investigator's role. It works best with set timelines and clear routing.